These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease. Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014 [TBL] [Abstract][Full Text] [Related]
9. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. Wang L; Ni M; Hückelhoven-Krauss A; Sellner L; Hoffmann JM; Neuber B; Luft T; Hegenbart U; Schönland S; Kleist C; Sill M; Chen BA; Wuchter P; Eckstein V; Krüger W; Hilgendorf I; Yerushalmi R; Nagler A; Müller-Tidow C; Ho AD; Dreger P; Schmitt M; Schmitt A Front Immunol; 2018; 9():2207. PubMed ID: 30349527 [TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis: what is it and when should it be used? Scarisbrick J Clin Exp Dermatol; 2009 Oct; 34(7):757-60. PubMed ID: 19663836 [TBL] [Abstract][Full Text] [Related]
11. The North American experience with photopheresis. Zic JA; Miller JL; Stricklin GP; King LE Ther Apher; 1999 Feb; 3(1):50-62. PubMed ID: 10079806 [TBL] [Abstract][Full Text] [Related]
12. Extracorporeal photopheresis for the treatment of autoimmune diseases. Adamski J; Kinard T; Ipe T; Cooling L Transfus Apher Sci; 2015 Apr; 52(2):171-82. PubMed ID: 25886694 [TBL] [Abstract][Full Text] [Related]
13. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. Weitz M; Strahm B; Meerpohl JJ; Bassler D Cochrane Database Syst Rev; 2014 Feb; (2):CD009898. PubMed ID: 24569961 [TBL] [Abstract][Full Text] [Related]
14. Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art. Martino M; Fedele R; Cornelio G; Moscato T; Imbalzano L; Ressa G; Massara E; Bresolin G Expert Opin Biol Ther; 2012 Aug; 12(8):1017-30. PubMed ID: 22587646 [TBL] [Abstract][Full Text] [Related]
15. Extracorporeal Photopheresis and Its Use in Clinical Dermatology in Canada. Lagacé F; Netchiporouk E; Turchin I; Gulliver W; Dutz J; Kirchhof MG; Popradi P; Gniadecki R; Lynde C; Litvinov IV Skin Therapy Lett; 2022 Sep; 27(5):1-6. PubMed ID: 36469458 [TBL] [Abstract][Full Text] [Related]
16. Extracorporeal photopheresis: a review on the immunological aspects and clinical applications. Chiesa-Fuxench ZC; González-Chávez J P R Health Sci J; 2010 Dec; 29(4):337-47. PubMed ID: 21261172 [TBL] [Abstract][Full Text] [Related]
17. An alternative for extracorporeal photopheresis: 8-methoxypsoralen and UVA-treated leucocytes from allogeneic donors improve graft-versus-host disease in mice. Budde H; Papert S; Reichardt HM; Jarry H; Riggert J; Legler TJ Vox Sang; 2018 Nov; 113(8):803-810. PubMed ID: 30353554 [TBL] [Abstract][Full Text] [Related]
18. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. McKenna KE; Whittaker S; Rhodes LE; Taylor P; Lloyd J; Ibbotson S; Russell-Jones R; ; Br J Dermatol; 2006 Jan; 154(1):7-20. PubMed ID: 16403088 [TBL] [Abstract][Full Text] [Related]
19. In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: New insights in extracorporeal photopheresis. Coppard C; Hannani D; Humbert M; Gauthier V; Plumas J; Merlin E; Gabert F; Chaperot L J Clin Apher; 2019 Aug; 34(4):450-460. PubMed ID: 30860623 [TBL] [Abstract][Full Text] [Related]